ystemic
glucocorticosteroid
steroid
commonli
prescrib
dyspneic
patient
wheez
studi
support
use
steroid
treatment
exacerb
copd
acut
asthma
condit
increasingli
recogn
infl
ammatori
syndrom
short
cours
system
steroid
shown
improv
spirometr
clinic
outcom
patient
copd
exacerb
although
patient
document
viral
infect
studi
precipit
exacerb
copd
asthma
includ
infect
environment
irrit
allergen
although
corticosteroid
reduc
infl
ammat
longterm
use
clear
detriment
rational
system
glucocorticosteroid
steroid
commonli
prescrib
patient
exacerb
copd
acut
viral
infect
respiratori
syncyti
viru
rsv
effect
shortterm
highdos
steroid
treatment
viral
load
adapt
immun
rsv
examin
adult
object
object
studi
measur
peak
viral
load
durat
viral
shed
serum
nasal
cytokin
rsvspecifi
c
antibodi
respons
lymphocyt
subset
patient
admit
hospit
rsv
infect
compar
patient
treat
steroid
patient
untreat
steroid
main
result
thirtythre
patient
hospit
rsv
receiv
system
steroid
mean
durat
day
receiv
steroid
frequent
wheez
less
often
febril
seriou
advers
event
relat
steroid
signifi
cant
differ
peak
viral
load
durat
rsv
shed
nasal
cytokin
lymphocyt
subset
patient
treat
steroid
patient
untreat
steroid
antibodi
respons
rsv
slightli
blunt
steroidtr
group
conclus
short
cours
system
steroid
patient
hospit
rsv
infect
affect
viral
load
shed
humor
immun
may
mildli
diminish
thu
potenti
benefi
ts
system
steroid
must
balanc
potenti
risk
abbrevi
alc
absolut
lymphocyt
count
asc
antibodi
secret
cell
pbmc
peripher
blood
mononuclear
cell
rsv
respiratori
syncyti
viru
rtpcr
revers
transcript
polymeras
chain
reaction
men
sputum
dilut
equal
volum
distil
water
vortex
extract
rsv
rna
detect
use
realtim
multiplex
rtpcr
identifi
rsv
b
infect
quantit
rtpcr
rsv
perform
use
publish
assay
modifi
ed
group
b
rsv
use
differ
revers
primer
tcctctatcagtccttgtt
standard
curv
run
assay
use
dilut
stock
rsv
plaqueform
unitsml
cyclic
threshold
valu
sampl
convert
pfu
per
ml
equival
serum
igg
nasal
iga
enzym
immunoassay
serum
neutral
assay
titer
serum
igg
nasal
iga
purifi
ed
rsv
f
g
glycoprotein
determin
use
establish
method
nasal
titer
standard
total
protein
gml
nasal
secret
neutral
titer
determin
microneutr
assay
previous
publish
cytokin
assay
serum
level
measur
use
commerci
avail
enzym
immunoassay
biosourc
camarillo
california
rang
detect
pgml
nasal
sampl
level
measur
use
commerci
enzym
immunoassay
kit
biosourc
cytokin
result
correct
gml
total
protein
polychromat
flow
cytometri
fresh
pbmc
whole
blood
stain
use
follow
antibodi
panel
identifi
tcell
subset
pacifi
c
biolegend
san
diego
california
petexa
invitrogen
carlsbad
california
alexa
bd
bioscienc
san
jose
california
b
cell
subset
fitcigd
peigg
alexa
bd
bioscienc
pacifi
sanz
laboratori
rochest
new
york
biolegend
invitrogen
cell
collect
lsrii
instrument
bd
bioscienc
confi
gure
detect
fl
uorochrom
one
million
event
collect
per
sampl
analysi
perform
use
flowjo
softwar
treestar
inc
version
total
pbmc
gate
lymphocyt
monocyt
use
forward
scatter
sideway
scatter
exclud
nonspecifi
c
stain
b
cell
use
respect
differ
categor
continu
distribut
evalu
fisher
exact
student
test
respect
twotail
mannwhitney
nonparametr
use
compar
nonsteroidand
steroidtr
fl
ow
data
overal
subject
identifi
ed
rsvinfect
rtpcr
agre
particip
studi
hospit
treat
outpati
thirtythre
inpati
receiv
least
day
system
corticosteroid
compar
three
outpati
analysi
immunolog
virolog
chang
associ
system
corticosteroid
use
restrict
effect
adapt
immun
glucos
control
bone
metabol
organ
system
respiratori
syncyti
viru
rsv
common
winter
viru
infect
person
age
associ
wheez
especi
young
children
children
rsvrelat
bronchiol
wheez
system
corticosteroid
studi
found
provid
signifi
cant
clinic
benefi
adult
viru
implic
caus
copd
asthma
exacerb
yet
rare
specifi
calli
diagnos
clinic
practic
wheez
associ
infect
system
corticosteroid
commonli
prescrib
howev
effect
shortterm
highdos
steroid
treatment
viral
load
adapt
immun
specifi
c
viru
acut
infect
never
examin
therefor
took
advantag
ongo
studi
pathogenesi
rsv
diseas
adult
address
issu
studi
conduct
three
consecut
winter
rochest
gener
hospit
rochest
new
york
hospit
patient
diagnos
upper
respiratori
infect
bronchiti
pneumonia
copd
asthma
viral
ill
respiratori
failur
evalu
within
h
admiss
particip
guardian
provid
inform
consent
univers
rochest
research
subject
review
board
rochest
gener
hospit
clinic
investig
committe
approv
studi
nasal
sampl
obtain
particip
rub
nasal
turbin
cotton
swab
revers
transcript
polymeras
chain
reaction
rtpcr
nasal
sampl
perform
within
h
collect
studi
subject
test
posit
rsv
visit
daili
expector
sputum
endotrach
aspir
secret
obtain
possibl
howev
sputum
induc
respiratori
sampl
collect
daili
fi
rst
day
ill
everi
day
thereaft
test
neg
rtpcr
two
consecut
sampl
nasal
sampl
also
collect
day
month
whole
blood
serum
collect
time
rsv
fi
rst
identifi
ed
day
month
symptom
onset
peripher
blood
mononuclear
cell
pbmc
isol
whole
blood
evalu
consist
medic
histori
chart
review
physic
examin
steroid
use
prior
admiss
time
dose
steroid
administr
hospit
record
subject
underw
daili
clinic
assess
hospit
reevalu
month
revers
transcriptionpolymeras
chain
reaction
rna
extract
l
water
l
respiratori
specipar
treat
vs
p
note
blood
sampl
collect
averag
day
steroid
begun
day
serum
level
similar
group
rsvspecifi
c
serum
nasal
antibodi
titer
measur
time
enrol
significantli
differ
group
serum
nasal
antibodi
respons
rsv
infect
slightli
blunt
steroidtr
group
fig
convalesc
titer
approxim
twofold
lower
compar
untreat
group
howev
serumneutr
antibodi
respons
group
viru
p
nasal
iga
fusion
protein
p
signifi
cantli
lower
twentynin
randomli
select
subject
steroid
treat
untreat
b
lymphocyt
subpopul
analyz
three
time
point
acut
h
initi
steroid
day
hospit
cohort
provid
balanc
ill
sever
comparison
group
although
varieti
steroid
regimen
prescrib
patient
receiv
mg
dexamethason
mg
methylprednisolon
everi
h
day
follow
oral
prednison
taper
mean
durat
steroid
therapi
day
rang
day
five
subject
receiv
fewer
day
corticosteroid
treatment
seven
subject
take
oral
corticosteroid
prior
admiss
given
iv
corticosteroid
higher
dose
oral
prednison
treatment
hospit
predict
clinic
featur
subject
receiv
corticosteroid
differ
treat
tabl
although
differ
achiev
statist
signifi
canc
given
steroid
hospit
often
men
histori
copd
receiv
oral
steroid
supplement
oxygen
prior
admiss
presenc
diabet
mellitu
coronari
arteri
diseas
slightli
common
among
treat
corticosteroid
admit
diagnos
similar
two
group
although
copd
exacerb
common
among
treat
steroid
diagnosi
pneumonia
lead
diagnosi
treat
wheez
time
admiss
common
steroid
group
wherea
patient
treat
steroid
patient
often
febril
although
signifi
cantli
differ
trend
toward
higher
rate
infi
ltrate
chest
radiograph
mean
peripher
wbc
count
treat
steroid
overal
hospit
cours
patient
receiv
corticosteroid
similar
treat
tabl
rate
respiratori
failur
intens
care
admiss
inhospit
mortal
signifi
cantli
differ
two
patient
steroidtr
group
die
case
patient
place
hospic
care
longstand
sever
copd
patient
develop
nosocomi
bacteri
infect
overt
complic
relat
steroid
treatment
psychosi
sever
glucos
dysregul
although
mean
last
day
report
wheez
dyspnea
significantli
longer
steroidtr
group
compar
treat
length
hospit
stay
ill
durat
signifi
cantli
differ
group
b
virus
evenli
distribut
treat
steroid
vs
treat
viral
shed
prolong
mean
viral
load
higher
steroidtr
group
fig
infl
ammatori
mediat
measur
nasal
sampl
enrol
day
day
consist
differ
either
group
tabl
trend
toward
lower
acut
serum
level
patient
treat
steroid
com
day
l
day
repres
fl
ow
cytometri
result
shown
figur
random
subset
patient
tand
bcell
panel
respect
mid
time
point
day
analysi
earli
late
test
demonstr
similar
fi
nding
band
tcell
subset
data
shown
repres
sampl
band
tcell
subset
shown
e
figur
signifi
cant
differ
steroidtr
steroiduntr
subject
time
point
note
regard
total
percentag
b
cell
memori
b
cell
antibodi
secret
cell
asc
plasmablast
fig
addit
signifi
cant
differ
fraction
cell
monocyt
cell
naiv
memori
natur
killer
cell
subset
fig
studi
patient
hospit
rsvrelat
respiratori
ill
shortterm
system
corticosteroid
associ
signifi
cant
advers
clinic
virolog
outcom
episod
sever
hyperglycemia
avascular
bone
necrosi
steroidinduc
psychosi
observ
hospit
followup
period
howev
import
note
studi
power
detect
import
clinic
steroidrel
advers
event
given
import
cellular
immun
viral
clearanc
recogn
effect
longterm
steroid
use
surpris
peak
rsv
viral
load
durat
viral
shed
increas
steroidtr
group
fi
nding
may
refl
ect
rel
brief
cours
system
steroid
receiv
studi
particip
although
steroid
exert
antiinfl
ammatori
effect
uniform
trend
detect
serum
nasal
cytokin
level
patient
receiv
steroid
complex
quantit
qualit
effect
system
glucocorticosteroid
host
immun
respons
well
describ
nearli
everi
type
immun
cell
includ
b
lymphocyt
neutrophil
monocyt
affect
substanti
reduct
circul
lymphocyt
demonstr
almost
immedi
upon
inject
hydrocortison
anim
studi
effect
increas
dose
durat
lymphopenia
revers
last
throughout
period
exposur
steroid
also
inhibit
tcell
activ
lymphocyt
prolifer
helper
helper
regul
given
known
effect
steroid
immun
system
lack
signifi
cant
differ
lymphocyt
number
subset
steroidtr
subject
day
post
ill
admiss
absolut
lymphocyt
count
alc
prior
steroid
administr
similar
l
vs
l
steroidtr
untreat
group
respect
notabl
steroidtr
group
two
receiv
steroid
prior
admiss
untreat
group
alc
l
present
hospit
receiv
steroid
repeat
measur
mean
alc
l
h
l
may
preferenti
affect
steroid
administr
studi
limit
small
sampl
size
lack
random
restrict
one
type
viral
infect
steroid
commonli
use
patient
copd
infl
ammatori
condit
effect
steroid
infl
ammatori
marker
immun
function
may
diffi
cult
discern
given
unequ
distribut
patient
copd
analysi
group
although
reason
presum
steroid
effect
would
similar
respiratori
virus
rsv
uniqu
immunomodulatori
effect
therefor
fi
nding
may
broadli
applic
conclus
short
cours
system
corticosteroid
patient
hospit
acut
rsv
infect
associ
major
deleteri
puzzl
howev
data
avail
immun
affect
steroid
acut
ill
patient
particularli
viral
infect
lymphopenia
associ
number
acut
viral
infect
infl
uenza
sever
acut
respiratori
syndrom
coronaviru
noteworthi
mani
patient
studi
lymphopen
time
present
thu
possibl
rsv
infect
induc
signifi
cant
immunolog
perturb
may
complic
interpret
steroid
effect
primari
advers
effect
steroid
use
appear
modestli
diminish
serum
secretori
antibodi
respons
although
differ
statist
signifi
cant
serumneutr
titer
group
viru
nasal
antibodi
f
protein
like
larger
sampl
size
would
yield
signifi
cant
differ
paramet
well
high
level
serum
nasal
rsv
antibodi
shown
protect
infect
sever
diseas
adult
although
specifi
c
protect
antibodi
titer
known
therefor
lower
postinfect
titer
may
leav
steroidtr
patient
suscept
futur
rsv
exposur
howev
absolut
differ
postinfect
antibodi
titer
observ
rel
small
make
clinic
implic
fi
nding
uncertain
diminish
antibodi
respons
steroid
group
explain
signifi
cant
reduct
number
b
lymphocyt
asc
tcell
lymphocyt
howev
possibl
function
activ
impair
despit
discern
differ
cell
number
subset
addit
measur
rsvspecifi
c
tcell
respons
asc
side
effect
sinc
specifi
c
respiratori
viral
infect
except
infl
uenza
rare
diagnos
adult
steroid
commonli
prescrib
acut
exacerb
copd
data
reassur
modestli
diminish
humor
respons
may
predispos
patient
futur
rsv
infect
risk
must
balanc
immedi
antiinfl
ammatori
effect
potenti
clinic
benefi
ts
